McMaster, Christopher

About Me


Dr. McMaster is the Scientific Director of the Canadian Institutes of Health Research (CIHR) Institute of Genetics and Professor of Pharmacology at Dalhousie University in Halifax, Canada, Previously, Dr. McMaster was the Carnegie and Rockefeller Professor and Head of the Department of Pharmacology, co-Director of the Cheminformatics Drug Discovery Lab, and Assistant Dean for Graduate and Post-doctoral Studies in the Faculty of Medicine at Dalhousie University. His research encompasses several genetic models ranging from yeast to zebrafish to mice with the aim of finding therapies for inherited diseases. He and his collaborators have identified a potential therapy for congenital sideroblastic anemia that is in Phase 2 trials, and has lead compounds undergoing development for the treatment of the inherited childhood blinding disorder familial exudative vitreoretinopathy and inherited Parkinson's disease. Dr. McMaster's interest in metabolic regulation also pointed toward the utility of small molecule inhibitors of lipid synthesis to treat drug resistant bacteria. Based on this concept, in 2006 he co-founded DeNovaMed, Inc., a Halifax based biotechnology company that specializes in using computer aided drug design to drive the synthesis and development of truly new classes of antimicrobials. Dr. McMaster has served as President of DeNovaMed since its inception and CEO since 2015. In 2012, DeNovaMed was ranked first from 142 companies in Nova Scotia in the provincial Innovacorp i3 competition for companies successfully implementing innovative concepts.

Other Details


Language(s):
Degrees / degrés: